Analyst Ratings For Exact Sciences
Portfolio Pulse from Benzinga Insights
Exact Sciences (NASDAQ:EXAS) received mixed analyst ratings, with 4 bullish and 3 somewhat bullish ratings. The average 12-month price target decreased by 7.78% to $77.0. Analysts adjusted their ratings and price targets, reflecting evolving market conditions. Exact Sciences, known for its cancer screening products, showed a 12.41% revenue growth but faces challenges with a negative net margin and ROE.

October 01, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Exact Sciences received mixed analyst ratings, with a decrease in the average price target to $77.0. Despite revenue growth, the company faces challenges with negative net margin and ROE.
The mixed analyst ratings and decrease in average price target suggest a neutral short-term impact on EXAS stock. While the company shows revenue growth, negative net margin and ROE present challenges, balancing the overall outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100